Business Context and Reporting Period
Company: Baxter International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2001
Business Overview: Baxter operates in three primary segments: Medication Delivery (infusion pumps, anesthesia), BioScience (biopharmaceuticals, blood collection), and Renal (kidney disease treatment). The company completed a 2-for-1 stock split in May 2001, and all share data is restated accordingly.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended June 30, 2001 |
6 Months Ended June 30, 2001 |
6 Months Ended June 30, 2000 |
|---|---|---|---|
| Net Sales | $1,870 | $3,627 | $3,277 |
| Net Income | $253 | $415 | $239 |
| EPS (Diluted) | $0.42 | $0.68 | $0.40 |
| Gross Margin | 44.2% | 44.0% | 43.8% |
| Cash & Equivalents | $431 | $431 | $496 |
| Total Debt (Short + Long Term) | $2,752 | $2,752 | $2,352 |
| Net Debt-to-Capital Ratio | 40.5% | 40.5% | 40.1% |
Cash Flow (6 Months 2001): Operating cash flow from continuing operations was a net outflow of $37 million, compared to an inflow of $152 million in the prior year. This was driven by increases in accounts receivable and inventories, and litigation payments. Investing activities resulted in a $375 million outflow, primarily for capital expenditures ($306 million) and acquisitions ($88 million).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% for the quarter and 11% year-to-date. Excluding currency fluctuations, sales growth was 15% (quarter) and 16% (year-to-date).
- Profitability: Net income from continuing operations increased significantly, driven by a $286 million in-process research and development (IPR&D) charge in Q2 2000 that did not recur in 2001. Pretax income from continuing operations rose from $13 million to $342 million for the quarter.
- Accounting Change: The adoption of SFAS No. 133 (Derivatives) resulted in a cumulative effect reduction to earnings of $52 million (net of tax) in Q1 2001, which is excluded from the Q2 comparison but impacts the six-month net income.
- Segment Performance:
- Medication Delivery: Sales up 6-7%; Pretax income up 14-17%.
- BioScience: Sales up 18-19% (driven by plasma products and Sera-Tec acquisition); Pretax income flat due to increased R&D.
- Renal: Sales up 5-7%; Pretax income down 8-11% due to product mix and currency.
Guidance, Outlook, and Risks
Management Commentary: Management expects gross profit margins to continue increasing and marketing/administrative expense ratios to decline for the remainder of the year. R&D expenses are expected to remain at current levels. The company aims to increase net sales in the low double digits and net earnings in the mid-teens for the full year 2001.
Subsequent Event: In August 2001, Baxter agreed to acquire ASTA Medica Oncology for approximately $470 million. A substantial portion of the purchase price is expected to be allocated to IPR&D and immediately expensed, though the acquisition is expected to be accretive to earnings in 2002.
Risks and Contingencies:
- Legal Proceedings: Significant litigation remains regarding mammary implants (382 lawsuits pending) and plasma-based therapies (HIV/Hepatitis C claims). Management believes reserves are adequate but acknowledges potential for future charges.
- Currency Risk: A strengthening U.S. dollar negatively impacted sales growth. Sensitivity analysis indicates a 10% unfavorable fluctuation could decrease the fair value of hedging contracts by approximately $221 million.
- Regulatory: Increased FDA activity regarding plasma-based biologicals poses a risk to operations.
Investor Verification Checklist
- Acquisition Impact: Verify the final allocation of the ASTA Medica purchase price and the magnitude of the immediate IPR&D expense charge.
- Litigation Reserves: Monitor updates on mammary implant and plasma therapy litigation settlements to ensure reserves remain adequate against potential excess charges.
- Cash Flow Trends: Assess whether the operating cash outflow in H1 2001 is a seasonal anomaly or indicative of working capital management issues (specifically inventory and receivables buildup).
- Debt Structure: Review the terms of the $800 million convertible debt issued in May 2001 and its impact on future interest expenses and potential dilution.
- Accounting Standards: Track the company's assessment of the impact of new standards SFAS 141 (Business Combinations) and SFAS 142 (Goodwill) on future financial reporting.